Table 3.

Pre-ASCT response rates and patients who underwent ASCT

OutcomeData setBV cohortChemotherapy cohortP
(χ2 test)∗ 		P (multivar)† 
nTotal%nTotal%
Underwent ASCT Whole 335 386 87% 324 382 85% .38 .064 
Underwent ASCT PET3 335 386 87% 130 157 83% .20 .23 
Underwent ASCT Matched 216 240 90% 199 240 83% .023 .020 
Underwent ASCT Whole, relapsed 156 173 90% 262 304 86% .20 .012 
Underwent ASCT Whole, refractory 179 213 84% 62 78 79% .32 .40 
Underwent ASCT Whole, stage IV 92 109 84% 91 117 78% .15 .29 
CMR PET 292 386 76% 126 157 80% .30 .23 
CMR Matched‡  193 240 80% 108 137 79% .69 .28 
CMR PET, relapsed 148 173 86% 78 90 87% .72 .75 
CMR PET, refractory 144 213 68% 48 67 72% .67 .11 
CMR PET, stage IV 74 109 68% 46 60 77% .22 .42 
ORR (PET) PET 343 386 89% 136 157 87% .46 .51 
ORR (PET) PET, relapsed 164 173 95% 81 90 90% .14 .11 
ORR (PET) PET, refractory 179 213 84% 55 67 82% .71 .43 
ORR (PET) PET, stage IV 90 109 83% 50 60 83% .90 .97 
ORR (CT) Whole 343 386 89% 300 382 79% < .001 < .001 
ORR (CT) Whole, relapsed 164 173 95% 238 304 78% < .001 < .001 
ORR (CT) Whole, refractory 179 213 84% 62 78 79% .36 .84 
ORR (CT) Whole, stage IV 90 109 83% 88 117 75% .18 .020 
CMR ICE/BeGEV§  PET 292 386 76% 105 157 67% .025 .0017 
CMR ICE/BeGEV Matched‡  193 240 80% 93 137 68% .005 .0040 
CMR ICE/BeGEV PET, relapsed 148 173 86% 67 90 74% .030 .007 
CMR ICE/BeGEV PET, refractory 144 213 68% 38 67 57% .067 .15 
CMR ICE/BeGEV PET, stage IV 74 109 68% 39 60 65% .69 .11 
OutcomeData setBV cohortChemotherapy cohortP
(χ2 test)∗ 		P (multivar)† 
nTotal%nTotal%
Underwent ASCT Whole 335 386 87% 324 382 85% .38 .064 
Underwent ASCT PET3 335 386 87% 130 157 83% .20 .23 
Underwent ASCT Matched 216 240 90% 199 240 83% .023 .020 
Underwent ASCT Whole, relapsed 156 173 90% 262 304 86% .20 .012 
Underwent ASCT Whole, refractory 179 213 84% 62 78 79% .32 .40 
Underwent ASCT Whole, stage IV 92 109 84% 91 117 78% .15 .29 
CMR PET 292 386 76% 126 157 80% .30 .23 
CMR Matched‡  193 240 80% 108 137 79% .69 .28 
CMR PET, relapsed 148 173 86% 78 90 87% .72 .75 
CMR PET, refractory 144 213 68% 48 67 72% .67 .11 
CMR PET, stage IV 74 109 68% 46 60 77% .22 .42 
ORR (PET) PET 343 386 89% 136 157 87% .46 .51 
ORR (PET) PET, relapsed 164 173 95% 81 90 90% .14 .11 
ORR (PET) PET, refractory 179 213 84% 55 67 82% .71 .43 
ORR (PET) PET, stage IV 90 109 83% 50 60 83% .90 .97 
ORR (CT) Whole 343 386 89% 300 382 79% < .001 < .001 
ORR (CT) Whole, relapsed 164 173 95% 238 304 78% < .001 < .001 
ORR (CT) Whole, refractory 179 213 84% 62 78 79% .36 .84 
ORR (CT) Whole, stage IV 90 109 83% 88 117 75% .18 .020 
CMR ICE/BeGEV§  PET 292 386 76% 105 157 67% .025 .0017 
CMR ICE/BeGEV Matched‡  193 240 80% 93 137 68% .005 .0040 
CMR ICE/BeGEV PET, relapsed 148 173 86% 67 90 74% .030 .007 
CMR ICE/BeGEV PET, refractory 144 213 68% 38 67 57% .067 .15 
CMR ICE/BeGEV PET, stage IV 74 109 68% 39 60 65% .69 .11 

3The PET dataset is the whole data set excluding patients from the study of Josting et al, in which response assessment was done by conventional CT scan only.

BeGEV, bendamustine, gemcitabine, etoposide, and vinorelbine; multivar, multivariable logistic regression analysis.

∗

P values from χ2 comparison of BV vs chemotherapy cohorts.

†

P values from multivariable logistic regression comparing BV vs chemotherapy cohorts corrected for baseline characteristics: R/R status, stage, B symptoms, extranodal disease, bulky disease, and primary treatment with escBEACOPP.

‡

For CMR calculations in the matched data set, patients from the study of Josting et al have been removed from the chemotherapy cohort, resulting in a smaller chemotherapy cohort of n = 137 patients instead of n = 240.

§

Comparison of pre-ASCT CMR rates measured after first sequential chemotherapy only. In the study of Moskowitz et al patients received sequential ICE and GVD chemotherapy in case of no CMR. In this comparison the response after ICE only is used in the chemotherapy cohort.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal